Edition:
United States

Tetraphase Pharmaceuticals Inc (TTPH.OQ)

TTPH.OQ on NASDAQ Stock Exchange Global Select Market

6.69USD
22 Nov 2017
Change (% chg)

$0.25 (+3.88%)
Prev Close
$6.44
Open
$6.44
Day's High
$6.75
Day's Low
$6.40
Volume
83,883
Avg. Vol
311,836
52-wk High
$9.69
52-wk Low
$3.59

Latest Key Developments (Source: Significant Developments)

Tetraphase Pharmaceuticals Q3 loss per share $0.63
Thursday, 2 Nov 2017 08:00am EDT 

Nov 2 (Reuters) - Tetraphase Pharmaceuticals Inc :Tetraphase pharmaceuticals reports third quarter 2017 financial results and highlights recent clinical and corporate achievements.Q3 loss per share $0.63.Q3 revenue $4.1 million versus $900,000.Q3 revenue view $1.3 million -- Thomson Reuters I/B/E/S.Q3 earnings per share view $-0.69 -- Thomson Reuters I/B/E/S.  Full Article

Tetraphase Pharmaceuticals signs commercial supply agreement with Finorga
Friday, 20 Oct 2017 04:28pm EDT 

Oct 20 (Reuters) - Tetraphase Pharmaceuticals Inc ::Tetraphase Pharmaceuticals Inc says ‍on October 16 co and finorga sas entered into a commercial supply agreement​ - sec filing.Tetraphase Pharmaceuticals - ‍under supply agreement finorga sas will make for commercial supply active pharmaceutical ingredient for eravacycline for co​.Tetraphase Pharmaceuticals- ‍supply agreement has initial term ending Oct 16, 2022.  Full Article

TETRAPHASE PHARMACEUTICALS APPOINTS KAM UNNINAYAR AS CFO
Monday, 16 Oct 2017 09:00am EDT 

Oct 16 (Reuters) - Tetraphase Pharmaceuticals Inc ::TETRAPHASE PHARMACEUTICALS APPOINTS KAM UNNINAYAR AS CHIEF FINANCIAL OFFICER.‍MOST RECENTLY, KAMALAM UNNINAYAR​ SPENT OVER 11 YEARS OVERSEEING FINANCE ORGANIZATIONS AT THERMO FISHER SCIENTIFIC.KAMALAM UNNINAYAR MOST RECENTLY SPENT OVER 11 YEARS OVERSEEING FINANCE ORGANIZATIONS AT THERMO FISHER SCIENTIFIC​.  Full Article

Tetraphase Pharmaceuticals presents clinical data from oral eravacycline development program at IDWEEK 2017​
Wednesday, 4 Oct 2017 08:00am EDT 

Oct 4 (Reuters) - Tetraphase Pharmaceuticals Inc :Tetraphase Pharmaceuticals - ‍phase 2 trial in patients with complicated urinary tract infections expected to begin in h1 2018​.Tetraphase pharmaceuticals presents clinical data from oral eravacycline development program at Idweek 2017.Tetraphase Pharmaceuticals Inc - expect topline data for ignite3 in q1 of 2018​.  Full Article

Tetraphase Pharmaceuticals completes enrollment of ignite3 phase 3 clinical trial of eravacycline
Monday, 11 Sep 2017 07:00am EDT 

Sept 11 (Reuters) - Tetraphase Pharmaceuticals Inc ::Tetraphase Pharmaceuticals completes enrollment of ignite3 phase 3 clinical trial of eravacycline in complicated urinary tract infections.Tetraphase Pharmaceuticals Inc - ‍company expects to report top-line data from trial in Q1 of 2018.​.Tetraphase Pharmaceuticals Inc - ‍plan to file a supplemental nda (snda) for iv eravacycline as a new treatment for patients with CUTI​.  Full Article

Tetraphase announces pricing of public offering of common stock
Thursday, 27 Jul 2017 08:21pm EDT 

July 27 (Reuters) - Tetraphase Pharmaceuticals Inc :Tetraphase announces pricing of public offering of common stock.Tetraphase Pharmaceuticals Inc - Pricing of an underwritten public offering of 10 million shares at $6.50 per share.  Full Article

Tetraphase announces proposed public offering of common stock
Wednesday, 26 Jul 2017 04:30pm EDT 

July 26 (Reuters) - Tetraphase Pharmaceuticals Inc :Tetraphase announces proposed public offering of common stock.Tetraphase Pharmaceuticals Inc - ‍has commenced an underwritten offering of $60 million of shares of its common stock​.  Full Article

Tetraphase announces positive top-line results from Phase 3 IGNITE4 Clinical Trial
Tuesday, 25 Jul 2017 04:01pm EDT 

July 25 (Reuters) - Tetraphase Pharmaceuticals Inc ::Tetraphase Pharmaceuticals announces positive top-line results from phase 3 IGNITE4 clinical trial in complicated intra-abdominal infections.Says IV Eravacycline achieves primary endpoint in second of two pivotal trials in cIAI.Says proceeding with regulatory submissions in Europe in Q3 2017 and U.S. in Q1 2018.Says ongoing phase 3 IGNITE3 clinical trial in cUTI expected to complete enrollment early Q4 2017.Tetraphase Pharmaceuticals - results of IGNITE4 demonstrated statistical non-inferiority of eravacycline to meropenem for primary efficacy endpoint.Tetraphase Pharmaceuticals - expects to provide update with top-line findings on phase 1 clinical testing of oral formulation of Eravacycline during Q3.  Full Article

Tetraphase Pharmaceuticals entered into amendment no. 1 to its controlled equity offering sales agreement dated Jan 17
Friday, 7 Jul 2017 04:49pm EDT 

July 7 (Reuters) - Tetraphase Pharmaceuticals Inc ::Tetraphase Pharmaceuticals - entered into amendment no. 1 to its controlled equity offering(sm)sales agreement dated jan 17.Tetraphase Pharmaceuticals - sole effect of amendment is to increase offering price of co's shares which co may issue up to $80 million from $40 million.  Full Article

Tetraphase Pharmaceuticals, Patheon UK enters into master manufacturing services agreement
Tuesday, 20 Jun 2017 04:43pm EDT 

June 20 (Reuters) - Tetraphase Pharmaceuticals Inc -:Tetraphase Pharmaceuticals - on June 14, 2017, tetraphase pharmaceuticals, Patheon UK Ltd and certain of its affiliates entered into master manufacturing services agreement.Tetraphase Pharmaceuticals - under master agreement co is responsible for supplying active pharmaceutical ingredient for eravacycline to patheon.Tetraphase Pharmaceuticals - expects to enter into 2 related product agreements to govern terms and conditions of patheon's manufacture of commercial supplies of eravacycline.Tetraphase Pharmaceuticals - master agreement initial term ends Dec 31, 2022, and will automatically renew after that for successive terms of 2 yrs each.  Full Article

BRIEF-Tetraphase Pharmaceuticals Q3 loss per share $0.63

* Tetraphase pharmaceuticals reports third quarter 2017 financial results and highlights recent clinical and corporate achievements